Login to Your Account



FDA 'Regrets' Panel's Lack of Expertise

Did FDA Rejection of Lorcaserin Lift Weight off Investors' Minds?

By Donna Young


Tuesday, October 26, 2010
WASHINGTON – The FDA unsurprisingly rejected Arena Pharmaceuticals Inc.'s weight-loss drug lorcaserin, with the much-disputed rat data, which have been the subject of controversy over the past month, remaining at the center of the agency's concerns. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription